131 related articles for article (PubMed ID: 24346093)
1. Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
Chen Y; Nowak I; Huang J; Keng PC; Sun H; Xu H; Wei G; Lee SO
J Thorac Oncol; 2014 Jan; 9(1):50-8. PubMed ID: 24346093
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
3. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells.
Chang KT; Tsai CM; Chiou YC; Chiu CH; Jeng KS; Huang CY
Am J Physiol Lung Cell Mol Physiol; 2005 Sep; 289(3):L446-53. PubMed ID: 15894558
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
Wan J; Wu W
J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM
Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
[TBL] [Abstract][Full Text] [Related]
7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
8. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
9. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
10. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway.
Guo X; Zhu X; Zhao L; Li X; Cheng D; Feng K
Tumour Biol; 2017 Mar; 39(3):1010428317694324. PubMed ID: 28345466
[TBL] [Abstract][Full Text] [Related]
12. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
[TBL] [Abstract][Full Text] [Related]
13. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells.
Carlisle DL; Liu X; Hopkins TM; Swick MC; Dhir R; Siegfried JM
Pulm Pharmacol Ther; 2007; 20(6):629-41. PubMed ID: 17015027
[TBL] [Abstract][Full Text] [Related]
14. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea S; Sage J
J Thorac Oncol; 2016 Aug; 11(8):1233-1241. PubMed ID: 27133774
[TBL] [Abstract][Full Text] [Related]
15. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
[TBL] [Abstract][Full Text] [Related]
16. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
17. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).
Zhao Q; Gu X; Zhang C; Lu Q; Chen H; Xu L
Cancer Biol Ther; 2015; 16(4):634-43. PubMed ID: 25778781
[TBL] [Abstract][Full Text] [Related]
18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
19. [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].
Tong XD; Liu HX; Zhao HR; Xu SG; Li Y; Han LB; Zhang L
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):741-5. PubMed ID: 17366784
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
